Australia markets closed

Benitec Biopharma Inc. (BNTC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2100+0.0200 (+10.53%)
At close: 12:59PM EST
0.2100 0.00 (0.00%)
Pre-market: 07:00AM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.1900
Open0.1843
Bid0.2100 x 800
Ask0.0000 x 900
Day's range0.1843 - 0.2198
52-week range0.1310 - 3.3000
Volume580,552
Avg. volume614,307
Market cap5.876M
Beta (5Y monthly)1.17
PE ratio (TTM)N/A
EPS (TTM)-2.1720
Earnings date13 Feb 2023 - 17 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.00
  • GlobeNewswire

    Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

    HAYWARD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year First Quarter ended September 30, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended September 30, 2022, with the U.S.

  • GlobeNewswire

    Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

    HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced it closed its previously announced underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying

  • GlobeNewswire

    Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering

    HAYWARD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the pricing of its underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purc